Goff Brian 4
4 · Intellia Therapeutics, Inc. · Filed Jun 10, 2026
Research Summary
AI-generated summary of this filing
Intellia (NTLA) Director Brian Goff Receives Equity Awards
What Happened
- Brian Goff, a director of Intellia Therapeutics (NTLA), was granted equity awards on June 9, 2026: 9,200 restricted stock units (RSUs) and a 13,300-share derivative award. Both grants show an acquisition price of $0.00 (typical for compensation awards) and were reported on a Form 4 filed June 10, 2026.
Key Details
- Transaction date: 2026-06-09; Form 4 filed: 2026-06-10 (timely filing).
- Awards: 9,200 RSUs (grant price $0.00) and 13,300-share derivative award (grant price $0.00).
- Shares owned after transaction: not specified in the provided summary (filing did not disclose total beneficial ownership here).
- Footnotes: F1 — the 9,200 awards are RSUs, each representing a contingent right to one share. F2 — the 13,300-share derivative award vests in full on the earlier of (a) the first anniversary of the grant or (b) the next annual meeting of stockholders.
- No cash changed hands; these are compensation grants (transaction code A).
Context
- These are grants of equity compensation, not open‑market purchases or sales, and are typically part of director pay rather than an immediate market bet. The derivative award has a short vesting trigger (up to one year or next annual meeting), so shares are not necessarily issued immediately.
Insider Transaction Report
Form 4
Goff Brian
Director
Transactions
- Award
Common Stock
[F1]2026-06-09+9,200→ 32,609 total - Award
Stock Option (right to buy)
[F2]2026-06-09+13,300→ 13,300 totalExercise: $12.89Exp: 2036-06-08→ Common Stock (13,300 underlying)
Footnotes (2)
- [F1]Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
- [F2]This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Signature
James Basta, attorney-in-fact|2026-06-10